Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Surgeon-Authored Virtual Laparoscopic Adrenalectomy Module Is Judged Effective and Preferred Over Traditional Teaching Tools.

Kurenov S, Cendan J, Dindar S, Attwood K, Hassett J, Nawotniak R, Cherr G, Cance WG, Peters J.

Surg Innov. 2017 Feb;24(1):72-81. doi: 10.1177/1553350616672971. Epub 2016 Oct 7.

2.

Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.

Marlowe TA, Lenzo FL, Figel SA, Grapes AT, Cance WG.

Mol Cancer Ther. 2016 Dec;15(12):3028-3039. Epub 2016 Sep 16.

3.

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.

Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, Dy GK.

Br J Cancer. 2016 Jul 12;115(2):203-11. doi: 10.1038/bjc.2016.190. Epub 2016 Jun 23.

4.

A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG.

Cell Cycle. 2014;13(16):2542-53. doi: 10.4161/15384101.2015.941760.

5.

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs.

Wilton J, Kurenova E, Pitzonka L, Gaudy A, Curtin L, Sexton S, Cance W, Fetterly G.

Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):55-67. doi: 10.1007/s13318-014-0233-6. Epub 2014 Nov 7.

6.

High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance WG.

BMC Cancer. 2014 Oct 17;14:769. doi: 10.1186/1471-2407-14-769.

7.
8.

Low dose four-dimensional computerized tomography with volume rendering reconstruction for primary hyperparathyroidism: How I do it?

Platz TA, Kukar M, Elmarzouky R, Cance W, Abdelhalim A.

World J Radiol. 2014 Sep 28;6(9):726-9. doi: 10.4329/wjr.v6.i9.726. Review.

9.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

10.

Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.

Gogate PN, Kurenova EV, Ethirajan M, Liao J, Yemma M, Sen A, Pandey RK, Cance WG.

Cancer Lett. 2014 Oct 28;353(2):281-9. doi: 10.1016/j.canlet.2014.07.032. Epub 2014 Jul 24.

11.

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.

Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG.

Eur J Med Chem. 2014 Jun 10;80:154-166. doi: 10.1016/j.ejmech.2014.04.041. Epub 2014 Apr 15.

12.

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.

Golubovskaya VM, Ho B, Conroy J, Liu S, Wang D, Cance WG.

Cancers (Basel). 2014 Jan 21;6(1):166-78. doi: 10.3390/cancers6010166.

13.

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.

Oncotarget. 2013 Oct;4(10):1632-46.

14.

Targeting the p53 pathway.

Golubovskaya VM, Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30. Review.

15.

Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Stewart JE, Ma X, Megison M, Nabers H, Cance WG, Kurenova EV, Beierle EA.

Mol Carcinog. 2015 Jan;54(1):9-23. doi: 10.1002/mc.22070. Epub 2013 Jul 19.

16.

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG.

BMC Cancer. 2013 Jul 11;13:342. doi: 10.1186/1471-2407-13-342.

17.

Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.

Heffler M, Golubovskaya VM, Dunn KM, Cance W.

Cancer Biol Ther. 2013 Aug;14(8):761-72. doi: 10.4161/cbt.25185. Epub 2013 Jun 3.

18.

Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Cance WG, Kurenova E, Marlowe T, Golubovskaya V.

Sci Signal. 2013 Mar 26;6(268):pe10. doi: 10.1126/scisignal.2004021. Review.

19.

MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.

Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG.

Anticancer Agents Med Chem. 2014 Jan;14(1):18-28.

20.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

Supplemental Content

Loading ...
Support Center